JUN and neoplasm: Further evidence for the role of c-Jun phosphorylation in the anti-tumour efficacy of TRX-E-002-1 comes from an experiment in OCSC2 cells incubated with the selective inhibitor of c-Jun N-terminal kinase, SP600125 [25].